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The modern era of stereotactic and functional neurosurgery has ushered in state of the
art technologies for the treatment of movement disorders, particularly Parkinson’s disease
(PD), tremor, and dystonia. After years of experience with various surgical therapies, the
eventual shortcomings of both medical and surgical treatments, and several serendipitous
discoveries, deep brain stimulation (DBS) has risen to the forefront as a highly effective,
safe, and reversible treatment for these conditions. Idiopathic advanced PD can be treated
with thalamic, globus pallidus internus (GPi), or subthalamic nucleus (STN) DBS. Thalamic
DBS primarily relieves tremorwhile GPi and STNDBS alleviate awide range of Parkinsonian
symptoms. Thalamic DBS is also used in the treatment of other types of tremor, particu-
larly essential tremor, with excellent results. Both primary and various types of secondary
dystonia can be treated very effectively with GPi DBS.The variety of anatomical targets for
these movement disorders is indicative of the network-level dysfunction mediating these
movement disturbances. Despite an increasing understanding of the clinical beneﬁts of
DBS, little is known about how DBS can create such wide sweeping neuromodulatory
effects. The key to improving this therapeutic modality and discovering new ways to treat
these and other neurologic conditions lies in better understanding the intricacies of DBS.
Here we review the history and pertinent clinical data for DBS treatment of PD, tremor, and
dystonia.Whilemultiple regions of the brain have been targeted for DBS in the treatment of
these movement disorders, this review article focuses on those that are most commonly
used in current clinical practice. Our search criteria for PubMed included combinations of
the following terms: DBS, neuromodulation, movement disorders, PD, tremor, dystonia,
and history. Dates were not restricted.
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INTRODUCTION
Movement disorders, particularly Parkinson’s disease (PD),
tremor, and dystonia, are among the most common neurological
diseases. Although patients with these disorders have signiﬁcantly
beneﬁted from the development of new pharmacological treat-
ments over time, many of these therapies have either not been
completely effective or not well-tolerated over the long course of
the disease (Olanow and Stern, 2008; Hauser, 2009). For exam-
ple, levodopa was initially felt to be the deﬁnitive treatment for
PD. However, as the disease progresses it often requires escalating
medication doses and frequencies to achieve the same treatment
effect. This can lead to rapidly cycling motor ﬂuctuations between
Abbreviations: ADLs, activities of daily living; BFMDRS, Burke–Fahn–Marsden
Dystonia Rating Scale; CT, computed tomography; DBS, deep brain stimulation; ET,
essential tremor; FDA, Food and Drug Administration; GPi, globus pallidus inter-
nus; HDE, human device exemption; HRQoL, health related quality of life; MPTP,
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MRI, magnetic resonance imaging;
PD,Parkinson’s disease; PDQ,Parkinson’s DiseaseQuestionnaire; STN, subthalamic
nucleus; TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale; UPDRS,
Uniﬁed Parkinson’s Disease Rating Scale; VIM, ventral intermediate; VL, ventral
lateral; Voa, ventral oralis anterior; Vop, ventral oralis posterior; WINCS, wireless
instantaneous neurotransmitter concentration system.
periods of mobility that may be accompanied by debilitating
dyskinesias and periods of severe akinesia (Goetz et al., 2005).
In response to these shortcomings, there have been signiﬁcant
advances over the last 15 years in stereotactic and functional neu-
rosurgical techniques as an alternative to pharmacological therapy.
These advances have led to new strategies in the treatment of
movement disorders (Nandhagopal et al., 2008; Remple et al.,
2008; Poewe,2009).An increased understanding of the pathophys-
iology of these neurological diseases has been coupled with these
technical improvements resulting in a signiﬁcant increase in the
application of restorative functional neurosurgical techniques to
treat movement disorders. Among these newer surgical therapies,
electrical stimulation of speciﬁc brain nuclei, known commonly as
deep brain stimulation (DBS), has become an increasingly popular
alternative strategy to traditional pharmacological treatment. DBS
involves the implantation of a microelectrode into a deep target
within the brain that is connected to a stimulator, which can be
programmed to emit electrical impulses at varying strengths and
frequencies (Figure 1). At this time,more than 80,000 people have
now been successfully implanted with DBS devices worldwide,
and this number is expected to grow exponentially (Medtronic,
2011). DBS is now FDA approved and is in routine clinical use for
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FIGURE 1 | Illustration of a DBS system with a microelectrode
implanted deep within the brain.This microelectrode is connected to a
programmable stimulator/battery that is typically implanted in the chest in
the subclavicular space. Permission to use this image granted by Mayo
Clinic.
treatment of PD, essential tremor, and dystonia (Koller et al., 2000;
Lozano, 2000; Bereznai et al., 2002; Krack et al., 2002; Greene,
2005). This review will focus on DBS treatment for these three
movement disorders.
THE EVOLUTION OF MODERN DAY STEREOTACTIC AND
FUNCTIONAL NEUROSURGERY
The history of DBS for the treatment of movement disorders
is a story marked with great triumphs, profound setbacks, and
serendipitous discoveries. Early neurosurgical treatment of move-
ment disorders focused on the treatment of PD. During the 1930s
and 1940s, a large number of patients suffered from posten-
cephalitic PD. Unfortunately, available medical therapy for this
devastating condition was limited leaving surgical therapies as the
main avenue of treatment. It was in this climate that the mod-
ern era of functional neurosurgery began to evolve. Initial surgical
treatments were based on the premise that tremor involved motor
function. Thus, if motor function was reduced or removed, the
tremor should stop. Early procedures included resections of the
premotor and motor cortex (Klemme, 1940; Bucy, 1942), pyrami-
dotomy (cutting the pyramidal tracts in the high cervical spinal
cord; Putnam, 1938), and pedunculotomy (incising the cerebral
peduncle in the midbrain;Walker, 1952).While each of these pro-
cedures was successful to some degree in alleviating Parkinsonian
tremor, they fell short as deﬁnitive treatments for two primary rea-
sons. First, it was at the great expense of motor function; second,
they had no effect on the remaining two primary symptoms of
PD: akinesia and rigidity.
It was in this atmosphere that the next major breakthrough
would come in the evolution of surgical treatment for movement
disorders. It is said that opportunity favors the prepared mind.
Such was the case for Irving Cooper. In October 1952, Cooper was
performing a pedunculotomy on a 39-year-old male. During the
surgical approach, an artery was torn resulting in severe bleeding.
Ultimately the artery was ligated and the procedure aborted. To
Cooper’s surprise, upon awakening the patient had resolution of
his tremor and rigidity, as well as preservation of motor function.
Postoperative angiogram showed the ligated artery was the ante-
rior choroidal artery (Das et al., 1998). Cooper (1953) concluded
that ligation of this artery resulted in infarction of the medial
globus pallidus and thus improved the patient’s symptoms. This
discovery led Cooper and others to logically turn the focus of sur-
gical treatment of PD from the pyramidal motor system to the
basal ganglia and eventually the thalamus. Lesioning techniques
of these anatomical locations by mechanical means, cryotherapy,
or electricity became the mainstay of surgical treatment for PD
(Benabid et al., 2009). As time progressed, techniques and results
improved. Indications were expanded to include tremor and dys-
tonia. However, this new strategy still had signiﬁcant drawbacks
includingdiminishing effect over time, surgical complications, and
cognitive decline when the procedures were performed bilaterally.
With these recent discoveries and developments, stereotactic
functional neurosurgery for the treatment of movement disorders
was exploding in the late 1950s. However, this success would be
short lived and another discovery would effectively knock stereo-
tactic functional neurosurgery from its pedestal and nearly into
extinction. In 1957, through the work of Arvid Carlsson, it was
discovered that cerebral dopamine was concentrated in the stria-
tum and that levodopa could reverse reserpine induced akinesia
(Carlsson et al., 1957). Ehringer andHornykiewicz (1960) showed
there was a depletion of striatal dopamine in PD patients. Ulti-
mately, Cotzias et al. (1967) tried levodopa as an alternative to
surgical therapy for PD and the initial results were nothing short
of miraculous. This new therapy alleviated akinesia, rigidity, and
tremor with immediate effects in a reversible and titratable man-
ner, effectively bypassing all of the complications of surgery with
better results (Benabid et al., 2009). This left little room for surgery
as a treatment for PD, and with time it became a forgotten therapy.
But as time would show, forgotten, but not lost.
Despite its initial success in treating PD, it was eventually
found that levodopa had long-term complications. After 5–7 years
of treatment, many patients began to cycle between periods of
mobility accompanied by debilitating dyskinesias and periods of
severe akinesia (Goetz et al., 2005). This left clinicians searching
for other alternatives for patients suffering from end stage PD.
There began to be a slow resurgence of ablative surgical therapies,
primarily pallidotomy for the treatment of PD and thalamotomy
for the treatment of tremor. Then, in 1987, another serendipi-
tous discovery occurred and once again, opportunity favored the
prepared mind. While performing a thalamotomy for tremor and
probing for the exact location for lesioning using electrical stimu-
lation, Benabid et al. (1987) discovered that at frequencies higher
than 100Hz, the patient’s tremor could be acutely and reversibly
modiﬁed. In essence, high frequency electrical stimulation of a
deep brain nucleus could mimic the effects of lesioning in a
reversible and safe manner. This discovery was groundbreaking
and led to the resurrection of stereotactic functional neurosurgery
in the treatment of movement disorders and the birth of DBS
techniques.
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Today, DBS is used to treat a wide variety of conditions. It
is not only the primary form of stereotactic functional neuro-
surgery used to treatmovement disorders,which is the focus of this
review, but is also used to treat epilepsy and psychiatric disorders
such as depression, obsessive compulsive disorder, and Tourette’s
syndrome as well (Tye et al., 2009). The future indications for
DBS will likely only continue to expand as our understanding of
neurocircuitry and neuromodulation grows.
DEEP BRAIN STIMULATION NEUROSURGICAL PROCEDURE
(TYE ET AL., 2009)
Current DBS surgical targets for the treatment of movement dis-
orders primarily include placement of an electrode in the subthal-
amic nucleus (STN), globus pallidus internus (GPi), and ventral
intermediate (VIM) thalamus. Although certain details regard-
ing the surgical technique may vary among different institutions,
all combine stereotactic technique with detailed image guidance.
Stereotaxis is a minimally invasive surgical procedure that makes
use of a three-dimensional coordinate system to locate accurately a
target in a deep-seated area of the brain and to perform on it some
action, such as electrophysiologic monitoring and placement of a
stimulating electrode. There are numerous designs for stereotac-
tic devices including: translational systems, arc-centered systems,
focal point systems, Polar coordinate systems, burr hole-mounted
devices, phantom target systems, computer-based systems, and
frameless systems.
Typically, a stereotactic head frame is placed on the patient
under local anesthesia in an operating room setting and a com-
puted tomography (CT) scan or, more commonly, a magnetic
resonance imaging (MRI) scan, is obtained to identify the ante-
rior commissure,posterior commissure,and themid-commissural
point. Based on the location of these structures, well-established
x, y, and z target coordinates are used for planning electrode
placement based on the patient’s pathology and target selected.
Commercially available planning software can then be used to
determine the target coordinates and an entry point that will allow
passage of the electrode through the brain without traversing the
ventricle or damaging vascular structures.
After appropriate imaging has been completed and an opera-
tive plan formulated, the patient is returned to the operating room,
where, under sterile conditions and local anesthesia, surgery com-
mences (Figure 2). A scalp incision and burr hole are placed in the
skull at the predetermined entry point. Microelectrode record-
ing is used to verify correct electrode placement in deep brain
nuclei. Following the placement of electrodes, test stimulation is
conducted using a temporary external stimulator. The patient is
kept awake to allow intraoperative evaluation of the therapeutic
beneﬁt of DBS. Further, verbal feedback from the awake patient
regarding unwanted side effects may also be evaluated. For exam-
ple, paresthesias with stimulationmay indicate current spread into
the somatosensory thalamus, or visual phenomena may represent
current spread to the optic tract. If such unwanted side effects
are noted, the electrode may be moved to another location. This
process essentially allows the neurosurgeon to functionally map
the patient speciﬁc to the patient’s own unique anatomy, neu-
rocircuitry, and stimulation threshold. Once the electrode is in
place, both intraoperative ﬂuoroscopy and postoperative MRI or
FIGURE 2 | Intraoperative photo of a patient undergoing DBS surgery
for Parkinson’s disease. As can be seen in the picture, patients are
typically kept awake during the surgery to clinically assess the efﬁcacy of
electrode placement with real time stimulation, as well as any unwanted
side effects. If the location is deemed suboptimal, it can easily be changed
intraoperatively and reassessed.
CT are utilized to conﬁrm proper placement (Figure 3). After
correct placement is conﬁrmed and trial stimulation is deemed
successful, a pulse generator is placed in the subclavicular space,
similar to a pacemaker. Stimulation parameters (frequency, ampli-
tude, pulse widths, etc.) vary based on the disorder being treated,
patient response, and the presence of side effects.
CLINICAL INDICATIONS
PARKINSON’S DISEASE
Parkinson’s disease is a chronic progressive neurodegenerative
movement disorder affecting the extrapyramidal motor system.
The central pathologic substrate of the disease is degeneration of
the dopaminergic neurons in the substantia nigra. Clinical hall-
marks of the condition classically include bradykinesia, rigidity,
and resting tremor (Gelb et al., 1999). PD is estimated to affect
approximately 1millionAmericans, roughly 1% of the population
over 60 years of age (Nutt and Wooten, 2005). As the population
ages, this number will only increase. As this disabling, chronic
disease progresses, it leads to a signiﬁcant loss in the quality of
life (Schrag et al., 2000). First line treatment for PD typically
includes dopaminergic medications, particularly levodopa. Ini-
tially, medical therapy is a very effective treatment, alleviating
symptoms and improving the quality of life. However, as the dis-
ease progresses it often requires escalating medication doses and
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FIGURE 3 | Postoperative MRI demonstrating placement of electrodes
in the STN bilaterally for treatment of idiopathic advanced PD.
frequencies to achieve the same treatment effect. This can lead to
rapidly cycling motor ﬂuctuations between periods of mobility
that may be accompanied by debilitating dyskinesias and periods
of severe akinesia (Goetz et al., 2005).
Some of the initial surgical therapies for PD have included
irreversible brain lesioning techniques such as thalamotomy and
pallidotomy (Cooper andBravo,1958; Svennilson et al., 1960;Mat-
sumoto et al., 1976; Cooper, 1977; Ohye et al., 1982; Laitinen et al.,
1992). While effective in reducing Parkinsonian symptoms, these
therapies often resulted in severe side effects such as dysarthria,dis-
equilibrium, visuospatial impairment, and homonymous hemi-
anopsia, with worse side effects occurring when the procedure
was performed bilaterally. Benabid et al. (1987) discovered that
high frequency stimulation of the VIM nucleus of the thalamus
could mimic the effects of this lesioning, but in a reversible and
adjustable manner, thereby reducing the adverse effects secondary
to the permanency of brain lesioning. This discovery opened a
new world of possibilities for stereotactic functional neurosurgery
and DBS.
In their published series, Benabid et al. (1991, 1996) demon-
strated that treatment with VIM thalamic DBS provided signiﬁ-
cant beneﬁt in the treatment of tremor, but not the other symp-
toms of PD. These studies conﬁrmed the efﬁcacy of DBS; however,
due to its limited effects on bradykinesia and rigidity when tar-
geting the thalamus, other neural targets were sought. Given the
previous success with pallidotomy in the treatment of PD, the
internal segment of the globus pallidus became a natural next tar-
get for stimulation (Laitinen et al., 1992). In addition, recent ani-
malmodels had shown increased glutamatergic output of the STN
in induced Parkinsonism (Robledo and Feger, 1990; Parent and
Hazrati, 1995). In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) treated primates, Bergman et al. (1990) showed that
lesioning of the STN, and Benazzouz et al. (1993) showed that
stimulation of the STN, both reduced all of the major symptoms
of PD. Thus, both GPi and STN were tried in human patients in
the treatment of advanced PD. Other investigated targets include
the zona incerta (Plaha et al., 2006), pedunculopontine tegmen-
tal nucleus (Stefani et al., 2007; Ferraye et al., 2010), and the
centromedian–parafascicular complex of the thalamus (Peppe
et al., 2008).
After years of research, the three currently accepted primary
targets used for DBS in the treatment of advanced PD refractory
to medical therapy are the VIM thalamus, GPi, and the STN (Pol-
lak et al., 2002). Each has associated beneﬁts and risks speciﬁc to
that target which are critical when considering patient selection
(Limousin and Martinez-Torres, 2008).
Thalamus
Although DBS of the VIM thalamus does not signiﬁcantly alter
bradykinesia or rigidity, it remains an effective target for treat-
ment of certain patients with tremor dominant PD refractory to
medical therapy (Benabid et al., 1991; Koller et al., 1997; Tasker,
1998; Limousin et al., 1999; Rehncrona et al., 2003). Initially, thala-
mic DBS was performed contralateral to thalamotomy to decrease
the morbidity associated with bilateral thalamotomy (Limousin-
Dowsey et al., 1999).However, over timemany studies have proven
VIM thalamic DBS to be a safe and effective treatment alternative
that has essentially replaced thalamotomy (Benabid et al., 1991;
Koller et al., 1997; Tasker, 1998; Limousin et al., 1999; Rehncrona
et al.,2003).Contralateral limb tremor is themost improved symp-
tom with thalamic DBS. Although there are some reports of mild
improvement in bradykinesia and rigidity, it is generally felt that
these are artifactual and secondary to the improvements in the
resting tremor (Limousin-Dowsey et al., 1999; Pollak et al., 2002).
Likewise, gait and postural stability do not improve with thalamic
DBS (Defebvre et al., 1996; Limousin et al., 1999; Pollak et al.,
2002). Despite its main limitation to tremor improvement, how-
ever, patients have signiﬁcant improvement in measures for both
quality of life and in performing the functional activities of daily
living (ADLs; Koller et al., 1997; Hariz et al., 1998; Woods et al.,
2001). Thalamic DBS has been shown to have long-term beneﬁt
for tremor control for more than 5 years postoperatively (Rehn-
crona et al., 2003; Hariz et al., 2007). Furthermore, patients are
able to maintain cognitive function after thalamic DBS (Schuur-
man et al., 2002).However, thalamicDBS does not typically reduce
drug dosage, due to its limited effects on other symptoms, and the
disease continues to progress despite tremor control (Limousin-
Dowsey et al., 1999; Hariz et al., 2007). Thus, VIM thalamic DBS
has fallen out of favor as a preferred target for the general treatment
of advanced PD, causing investigators to focus on other targets. In
fact, Fraix et al. (2005) have shown signiﬁcant improvement in
all major Parkinsonian symptoms in patients previously treated
with thalamic DBS who subsequently underwent STN DBS. Nev-
ertheless, thalamic stimulation remains an option in appropriate
advanced PD patients who are either tremor predominant or are
not candidates for other targets. Like thalamotomy, thalamic DBS
side effects can include dysarthria and worsening balance (Tasker,
1998). While these symptoms can effectively be controlled with
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adjusting the level of stimulation, they should still be weighed
carefully in patient selection for this procedure.
Globus pallidus internus
Deep brain stimulation of the GPi was initially proposed as an
alternative to pallidotomy to decrease patient morbidity. This pro-
cedure has been performed on patients since 1994. Since then,
numerous studies have demonstrated overall signiﬁcant improve-
ments in patients with advanced PD treated with GPi DBS (Ghika
et al., 1998; Volkmann et al., 1998; Kumar et al., 2000; Durif et al.,
2002; Loher et al., 2002; Lyons et al., 2002; Rodrigues et al., 2007b).
Improvements in both gait and posture have also been shown
(Volkmann et al., 1998; Grasso et al., 1999). Furthermore, remark-
ablemotor and non-motor quality of life improvements have both
been well documented (Vingerhoets et al., 1999; Rodrigues et al.,
2007a). Notably, the most consistent beneﬁcial effect seen from
GPi DBS is in the reduction of dyskinesias (Ghika et al., 1998;
Volkmann et al., 1998, 2004; Kumar et al., 2000; Durif et al., 2002;
Loher et al., 2002; Lyons et al., 2002; Rodrigues et al., 2007b).
Many patientswith PDwhohave been treated chronicallywith lev-
odopa suffer from dyskinesias and motor ﬂuctuations. They cycle
between periods of good mobility while taking levodopa (“on”
periods) and impaired mobility while off levodopa (“off” periods;
Lang and Lozano, 1998). These ﬂuctuations are often refractory
to changes in medical therapy and very debilitating. Thus, it is in
this population that GPi DBS has been most successful. This is felt
to be a direct effect of the high frequency stimulation, as studies
demonstrate no signiﬁcant decrease in levodopa dose reduction
postoperatively that could otherwise alter dyskinesias (Limousin
and Martinez-Torres, 2008). GPi DBS has also been reported to
reduce both the amount and severity of on/off ﬂuctuations (Ghika
et al., 1998; Volkmann et al., 1998; Loher et al., 2002; Lyons et al.,
2002).
While the beneﬁt in dyskinesia control is relatively universal
in the current literature for GPi DBS, there is some variability in
other outcome measures. Most studies show no signiﬁcant differ-
ence between preoperative and postoperative “on” period Uniﬁed
Parkinson’s Disease Rating Scale (UPDRS) motor scores over time
(Ghika et al., 1998; Kumar et al., 2000;Durif et al., 2002;Volkmann
et al., 2004; Rodrigues et al., 2007b). However, there are consid-
erable differences in the magnitude of changes seen between the
pre- and postoperative “off” period UPDRS motor scores, as well
as differences in the type of off-drug symptoms improved (Ghika
et al., 1998; Kumar et al., 2000; Durif et al., 2002; Lyons et al., 2002;
Volkmann et al., 2004; Rodrigues et al., 2007b). Some authors pos-
tulate that these differences may be explained by the complexity
of GPi connections (Bejjani et al., 1997; Krack et al., 1998a; Gross
et al., 1999; Limousin andMartinez-Torres, 2008).When different
areas of the GPi are stimulated there are different clinical results.
Both Bejjani et al. (1997) and Krack et al. (1998a) showed that
stimulation of the ventral portion of the globus pallidus resulted
in improvement in rigidity and dyskinesias but often times can
induce akinesia; on the other hand, stimulation of the dorsal
GPi caused improvement in rigidity and akinesia, but induced
dyskinesias in a number of patients.
Over time, the reduction of dyskinesias persists for greater than
4–5 years in available long-term studies (DBS Study Group, 2001;
Volkmann et al., 2004). However, some studies show a gradual
decrease in the beneﬁt for off medication symptoms over time
(DBS StudyGroup, 2001;Durif et al., 2002;Volkmann et al., 2004).
Furthermore, the improvements in ADLs have also been shown
to be lost after the ﬁrst year (Volkmann et al., 2004). The grad-
ual reduction in some of the clinical beneﬁts over time and the
complexity of the globus pallidus connections resulting in vari-
able clinical outcomes have caused some clinicians to prefer other
DBS targets. Some of the reported side effects related to the target
include paresthesias, muscle contractions, visual ﬂashes, wors-
ening akinesia, dysarthria, weight gain, eyelid opening apraxia,
confusion, and cognitive decline (Limousin and Martinez-Torres,
2008). Nevertheless, DBS of the globus pallidus has proven to be
a safe procedure with lowmorbidity that can beneﬁt patients with
advanced PD, particularly those with severe motor ﬂuctuations.
Subthalamic nucleus
Deep brain stimulation of the STNhas evolved to become themost
promising surgical treatment of medically refractory, advanced
PD. Studies have consistently shown thatDBSof the STN improves
bradykinesia, rigidity, tremor, postural control, and gait (Limou-
sin et al., 1995, 1998; Kumar et al., 1998; Moro et al., 1999; Pinter
et al., 1999; Houeto et al., 2000; Molinuevo et al., 2000; Herzog
et al., 2003; Kleiner-Fisman et al., 2003; Krause et al., 2004b). Off
medication motor symptoms seem to improve most signiﬁcantly,
with reported improvements averaging between 40 and 60% on
the standardized UPDRS (Kumar et al., 1998; Limousin et al.,
1998; Moro et al., 1999; Pinter et al., 1999; Molinuevo et al., 2000;
Kleiner-Fisman et al., 2003; Krause et al., 2004b). The dose of lev-
odopa is also markedly reduced with an associated reduction in
levodopa induced dyskinesias (Kumar et al., 1998; Limousin et al.,
1998;Moro et al., 1999; Fraix et al., 2000; Houeto et al., 2000;Volk-
mann et al., 2001;Kleiner-Fisman et al., 2003;Krause et al., 2004b).
Molinuevo et al. (2000) have even shown that completewithdrawal
of levodopa is feasible with bilateral STN DBS. Multiple studies
have also demonstrated signiﬁcant quality of life improvements
in not only those measures related to motor beneﬁts, but also
in the mental, emotional, social, cognitive, and communicative
aspects of life (Kumar et al., 1998; Lagrange et al., 2002; Martinez-
Martin et al., 2002; Lezcano et al., 2004; Lyons and Pahwa, 2005).
This beneﬁt has been shown to be associated with quality of life
improvements in the patient’s caregiver as well (Lezcano et al.,
2004). There have also been reports of non-motor improvement
in constipation, sleep, sensory complaints, bladder symptoms, and
urodynamics (Moro et al., 1999;Cicolin et al., 2004; Seif et al., 2004;
Winge et al., 2007; Witjas et al., 2007; Zibetti et al., 2007).
In a randomized controlled trial of STN DBS vs. best medical
management, DBS was shown to be superior to medical man-
agement alone (Deuschl et al., 2006). Deuschl et al. enrolled 156
patients with advanced PD and severe motor symptoms in the
study. Primary endpoints included changes in the quality of life
as measured by the Parkinson’s Disease Questionnaire (PDQ-
39) and severity of symptoms off medication per the UPDRS-III
after 6months. Neurostimulation resulted in signiﬁcantly greater
improvements in both the quality of life and the severity of motor
symptoms. Serious adverse events were more common in the sur-
gical group (including one patient death), but overall adverse
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events weremore common in themedication group. In addition to
being superior to best medical management alone in advanced PD
patients, STNDBS has also been shown to be a cost effective treat-
ment of PD. Fraix et al. conducted a multicenter prospective study
of 95 consecutive PDpatients treatedwith bilateral STNDBS.They
compared the cost of the disease for a 6-month period before the
surgery and a 6-month period after the surgery and found there
was a signiﬁcant decrease in the cost from 10,087 euros before
surgery to 1673 euros after surgery (p< 0.0001), mainly due to a
decrease in the need for medication (Fraix et al., 2006).
Initial criticism of DBS as a therapeutic modality cited a lack
of long-term follow up in these patients raising questions about
harmful effects of chronic stimulation and whether or not initial
beneﬁts were sustained over time. Now, long-term follow up of
STN DBS patients is available and shows signiﬁcantly sustained
beneﬁt years after surgery. Krack et al. (2003) found that patients
treated with bilateral STN DBS continued to have signiﬁcant ben-
eﬁt in both off medication motor symptoms and on medication
dyskinesias 5 years after surgery. However, while there was no con-
trol group in this study, worsening of akinesia, speech, postural
stability, freezing of gait, and cognitive function worsened over
this period of time consistent with the natural history of the dis-
ease. This suggests that while STN DBS can alter symptoms and
greatly improve quality of life, it does not alter disease progression.
Schupbach et al. (2005) also found that 5 years after surgery there
were sustained signiﬁcant improvements in ADLs and parkinson-
ian motor disability scores in both the off and on drug states
per UPDRS criteria. Furthermore, the severity of levodopa related
dyskinesias and daily doses were signiﬁcantly reduced after 5 years.
Once again,moderate motor and cognitive decline was noted over
time,which was felt to be due to natural progression of the disease.
Wider et al. (2008) found similar results with sustained beneﬁt
after 5 years.
Side effects observed after STN DBS include dysarthria, neu-
ropsychiatric problems, cognitive deterioration, eyelid opening
apraxia, weight gain, stimulation induced dyskinesias, and wors-
ening akinesia if leads are placed too deeply (Pollak et al., 2002;
Limousin and Martinez-Torres, 2008). Cognitive decline has been
a closely scrutinized trend after surgery. As noted above, studies
showing long-term sustained beneﬁt in parkinsonian symptoms
after STN DBS also note progressive motor and cognitive decline
over time (Rodriguez-Oroz et al., 2005; Schupbach et al., 2006).
Aybeck et al. prospectively investigated the long-term cognitive
proﬁle and incidence of dementia in 57 PD patients treated with
STN DBS over a 3-year period. They found that the incidence of
dementia over this time period was similar to that reported in
medically treated patients and was more likely secondary to the
natural evolution of the disease rather than a direct effect of STN
DBS (Aybek et al., 2007). Another study conducted by Funkiewiez
et al. (2004) focused on the cognitive,mood, and behavioral effects
of STNDBS and found that only two cognitive variables worsened
(category ﬂuency and total score of ﬂuency) and concluded that
STN stimulation did not lead to global cognitive decline. Interest-
ingly, in their study depression improved, but apathy and thought
disorders worsened.
As with other DBS targets in PD patients, appropriate patient
selection is critical for success. Patients felt to be the best candidates
for STNDBS typically have relatively youngonset of disease,highly
levodopa-sensitive PD, and suffer from severe motor complica-
tions of long-term dopaminergic treatment (Pollak et al., 2002).
Levodopa sensitivity is felt to be one of the best predictors of
STN DBS success (Krack et al., 2000; Kleiner-Fisman et al., 2003).
Patients with preoperative cognitive decline or dementia are at
risk for accelerated worsening after STN DBS (Aybek et al., 2007).
Age at the time of surgery has also been found to be a variable
to consider. Derost et al. (2007) showed that postoperative quality
of life assessments were better in patients less than 65 years of age
undergoing STNDBS than those that were older. Ory-Magne et al.
(2007) found that there was a signiﬁcant negative correlation with
age and quality of life improvement as measured by the PDQ-39.
GPi vs. STN
Many studies have been performed on these targets individually;
however, there is limited data comparing the two targets together.
While a number of studies include groups of patients implanted
with electrodes in the GPi as well as other patients with elec-
trodes in the STN, the majority of these are not randomized or
blinded (Krack et al., 1998b; DBS Study Group, 2001; Krause et al.,
2001; Volkmann et al., 2001; Peppe et al., 2004; Rodriguez-Oroz
et al., 2005). Anderson et al. (2005) published a prospective, ran-
domized, blinded study of 10 patients with GPI implants and 10
patients with STN implants for treatment of advanced PD. Out-
comes were measured using the UPDRS-III scale assessed at 3, 6,
and 12months postoperatively. After 12months there was little
difference between the groups with a 48% improvement in the
UPDRS-III in the STN group and 39% improvement in the GPi
group. Dyskinesias were reduced by 89% in the GPi group com-
pared to 62% in the STN group. Bradykinesia tended to improve
more and there was more of a decrease in levodopa dosage with
STN stimulation. However, cognitive and behavioral complica-
tions were observed only in combination with STN stimulation.
In a more recent and larger study, Follett et al. (2010) published
a prospective, randomized, multicenter, blinded study in which
299 patients with idiopathic PD were assigned to undergo either
GPi (152 patients) or STN (147 patients) stimulation. The pri-
mary outcome was the change in motor function based on the
UPDRS-III while receiving stimulation but no antiparkinsonian
medication. Secondary outcomes included self-reported function,
quality of life, neurocognitive function, and adverse events. At
24months, mean changes in the primary outcome did not differ
between the groups. Furthermore, there was no signiﬁcant differ-
ence in self-reported function. Consistent with previous studies,
patients with STN stimulation required less dopaminergic med-
ication. The level of depression worsened after STN DBS, but
interestingly improved after GPi DBS. There were no signiﬁcant
differences in adverse events. Based on these studies and available
data, most clinicians would agree that motor function improves
similarly with both STN and GPi stimulation, but non-motor
factors need to be considered before choosing a stimulation site.
TREMOR
Essential tremor
Essential tremor is the most common movement disorder affect-
ing up to 5.5% of individuals aged 65 years or older (Louis et al.,
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2009). Patients with essential tremor experience rhythmic, invol-
untary movements with active movement or posture. The arms,
head, and voice are the areas of the body most frequently affected
(Bain et al., 1994). The cause of essential tremor is unknown, but
a strong genetic component is likely given the high frequency of
familial occurrence (Busenbark et al., 1996).
In most affected individuals, essential tremor remains a mild
disease. However, in some the tremor escalates in severity and
results in signiﬁcant disability (Busenbark et al., 1991). Hand and
arm tremor can impair eating, drinking, handwriting, and groom-
ing. Involuntary head shaking may result in embarrassment and
social withdrawal.Voice tremor can impair communication.Med-
ication, in particular beta blockers and primidone, often provide
signiﬁcant relief of disabling arm tremor. Botulinum toxin ther-
apy is sometimes useful for head and voice tremors. There remain,
however, those severely affected patients in whommedical therapy
fails and functional neurosurgery is considered.
In 1955, Cooper introduced surgical therapy of Parkinsonian
tremor using targeted lesions in the ventral thalamus (Cooper,
1981). Over time, surgery targeting the ventral lateral (VL) nucleus
of the thalamus became the effective lesioning site for essen-
tial tremor. Thalamotomy was shown to have marked beneﬁt in
essential tremor and was performed predominately unilaterally
(Goldman et al., 1992). Bilateral thalamotomy is rarely employed
and carries an increased risk of lasting dysarthria (Zirh et al., 1999).
Benabidmade the fundamental discovery that continuous high
frequency stimulation of the ventral thalamus could alleviate
tremor without the risk of permanent side effects (Benabid et al.,
1991). Further studies conﬁrmed that DBS had a profound ben-
eﬁt in essential tremor (Hubble et al., 1996; Ondo et al., 1998;
Koller et al., 1999; Limousin et al., 1999). These reports led to a
direct comparison study of thalamotomy and DBS of the thal-
amus for treatment of tremors, including essential tremor. This
study reported signiﬁcant tremor suppression in both treatment
groups. However, thalamic stimulation resulted in greater reduc-
tion in tremor, better functional outcome, and fewer side effects.
With these ﬁndings thalamic stimulation has become the surgi-
cal therapy of choice for medically intractable essential tremor.
Long-term follow up is available showing that the beneﬁt from
thalamic stimulation is maintained. In 19 patients with essential
tremor followed for an average of 6.7 years improvement in upper
limb tremor remained marked over the entire period of observa-
tion (Sydow et al., 2003). An added beneﬁt of thalamic stimulation
is the apparent safety of bilateral procedures (Pahwa et al., 1999;
Ondo et al., 2001). Dysarthria remains a frequent complication
of bilateral stimulation, however, when dysarthria does occur it is
generally mild and reversible (Pahwa et al., 2006).
The usefulness of thalamic stimulation in the treatment of
essential head and voice tremor remains unproven. While sev-
eral small series report improvement with bilateral stimulation,
long-term studies in larger groups of patients are needed (Taha
et al., 1999; Putzke et al., 2005).
Cerebellar tremor
Lesions involving the cerebellum and its outﬂow or inﬂow tracts
can result in tremor.Cerebellar tremor is distinguishedby the com-
bination of postural tremor with intention tremor-the worsening
of tremor especially at the end of a visually guided movement
(Deuschl et al., 1998). When tremor also is visible at rest the term
“Holmes” tremor is preferred, although “rubral,” “midbrain,” or
“thalamic” tremors have also been used. Cerebellar tremor can be
seen as a result of lesions as diverse as multiple sclerosis, stroke,
trauma, cavernous hemangiomas, tumors, or degenerative dis-
ease. Over the past decade, DBS has been an emerging therapy
for disabling cerebellar tremor of many different etiologies.
Tremor of multiple sclerosis
The inﬂammatory lesions of multiple sclerosis frequently affect
cerebellar inﬂow or outﬂow pathways. These lesions individually
or in combination may result in tremor often in combination
with ataxia (Feys et al., 2005). In a population-based study tremor
was present in 25% of patients with multiple sclerosis and in 3%
it was severe (Pittock et al., 2004). The severe cerebellar tremor
of multiple sclerosis is often disabling and impairs even the most
rudimentary functions.Medical and physical therapy is ineffective
and surgical therapy is often considered.
Cooper (1960) ﬁrst reported the use of thalamotomy to alle-
viate tremor in multiple sclerosis and reported relief of tremor
in 80–100% of patients. However, experience over the subsequent
20 years raised concern. Speelman reported that a reduction in
intention tremor could be almost uniformly achieved with thal-
amotomy, however, improvement in functional status was not
demonstrable. In addition the complication rates were high and
often included serious events such as limb weakness, dysarthria,
or disease relapse (Speelman and Van Manen, 1984).
Given the concerns raised by thalamotomy inmultiple sclerosis
patients, DBS with its reversible effects seemed to offer advantage.
Geny reported that VIM stimulation reduced tremor in 69% of
multiple sclerosis patients. The operation was tolerated without
major complications, but functional improvement was minimally
improved (Geny et al., 1996). Long-term studies of DBS in mul-
tiple sclerosis echo these ﬁndings. One year after implantation,
patients demonstrated lasting beneﬁt in tremor control (Hooper
et al., 2002; Berk et al., 2004). Improvement in feeding activi-
ties was found in some but functional capacity was otherwise
unchanged.
Thalamic stimulation has been compared to thalamotomy in
multiple sclerosis patients. In one study, lesional surgery had a
greater degree of suppression of tremor, but stimulation had fewer
severe complications (Bittar et al., 2005). In another comparison
of 10 patients randomly assigned to thalamotomy or thalamic
stimulation there was no difference between the therapies and
the effects of both tended to wane at 5 years (Schuurman et al.,
2008). A metaanalysis of all available studies addressed this issue
and concluded that effective tremor reduction followed both thal-
amotomy (94%) and DBS (96%) and both were associated with
signiﬁcant complications. Both therapies have advantages and dis-
advantages and these need to be discussed with each patient (Yap
et al., 2007). From these studies one can conclude that patients
with tremor from multiple sclerosis should be carefully selected
before either thalamic DBS or thalamotomy is undertaken. The
best candidates would have stable disease and impairment entirely
from limb tremor and not from ataxia or weakness. Preoperative
counseling is key in preparing the patient for the best result which
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is reduction in tremor with unpredictable and perhaps only mild
beneﬁt on limb function (Critchley and Richardson, 1998).
Post-traumatic and post-stroke tremor
Cerebellar tremor can follow head trauma (Biary et al., 1989).
In closed head trauma the responsible lesion has been shown in
the dentatothalamic cerebellar outﬂow pathway and likely result
from shear injury (Krauss et al., 1995). Likewise stroke, either
infarction or hemorrhage, in these regions can result in a delayed
onset cerebellar tremor (Alarcon et al., 2004). When severe these
tremors result in persistent disability as medication treatment is
not available.
Post-traumatic tremor has been less responsive than other
tremors to thalamotomy. In a comparative study moderate to
marked improvement in tremor was observed in 86% of Parkin-
son’s disease patients, 83% of the patients with essential tremor,
67% of the patients with various cerebellar tremors, and 50% of
the patients with post-traumatic tremor (Jankovic et al., 1995).
Krauss reported a large series of 35 patients with tremor following
head injury treated with stereotactic lesions of the ventral thala-
mus or zona incerta (Krauss et al., 1994). A marked or complete
tremor reduction was achieved in 65 and 88% had some degree
of improvement. An incomplete but signiﬁcant improvement in
disability was recorded. A beneﬁcial effect of thalamic stimulation
has been reported in individual cases of post-traumatic or post-
stroke tremor (Broggi et al., 1993; Nguyen and Degos, 1993; Geny
et al., 1995).
Recently, dual deep brain stimulator leads were used to span a
larger region of the ventral thalamus (VIM, Voa, and Vop) result-
ing in better control in post-traumatic tremor (Foote and Okun,
2005). The use of multiple targets in DBS provides a possible
avenue for improving the results in this and other forms of severe
cerebellar tremor (Foote et al., 2006).
Orthostatic tremor
Orthostatic tremor is a rare syndrome in which high frequency
12–18Hz tremor bursts appear immediately upon standing and
cause severe postural instability. The tremor may be responsive to
pharmacologic agents such as clonazepam or gabapentin. How-
ever, many patients fail to respond or become tolerant to these
agents.
Recently, case reports of bilateral thalamic stimulation in three
patients have demonstrated beneﬁcial effects in treatment resistant
orthostatic tremor (Espay et al., 2008; Guridi et al., 2008). These
preliminary reports hold promise that DBS may be an effective
therapy for this disabling disorder.
DYSTONIA
Dystonia is a family of movement disorders in which sustained
muscle contractions lead to twisting, abnormal posture, relentless
muscle spasm, or other unwanted repetitive movements (Fahn
et al., 1998). It is the most common type of movement disorder
after PD and tremor. There are several ways in which dystonia
can be classiﬁed. First, it is classiﬁed as either primary or sec-
ondary dystonia. Primary or idiopathic dystonia occurs in the
absence of other neurologic signs and without abnormalities
on neuroimaging. Secondary dystonia is due to some identiﬁed
cause, such as stroke, trauma, drugs (tardive dystonia), or is the
result of another neurologic disorder such as Wilson’s disease.
Dystonia may also be classiﬁed based on anatomical distribu-
tion and includes generalized, segmental, and focal dystonias.
Focal dystonias may include cervical dystonia (spasmodic torti-
collis), blepharospasm, oculogyric crisis, oromandibular dystonia,
spasmodic dysphonia/laryngeal dystonia, and focal hand dystonia
(also known as musician’s or writer’s cramp). The combination
of blepharospasmodic contractions and oromandibular dystonia
is called cranial dystonia or Meige syndrome. Interestingly, task-
related factors are sometimes suspected to cause focal dystonia as
they may appear in patients who perform high precision move-
ments such asmusicians, engineers, and golfers,where the dystonia
is termed “yips.” Dystonia may also be classiﬁed based on patient
genotype. Several genes have been linked to hereditary forms of
dystonia,with theTOR1A locus (previouslyDYT1) being themost
well known (Ostrem and Starr, 2008).
Although there is currently no cure for dystonia, there are
multiple treatment options available. Medical options include
treatmentwith anticholinergics, tetrabenazine,antiepileptics,ben-
zodiazepines, baclofen, and botulinum toxin for focal or segmental
dystonias.While many patients beneﬁt from these therapies,many
of these treatments fall short and surgical treatments are con-
sidered. As with other movement disorders, lesioning techniques
comprised early surgical therapies for the treatment of dystonia,
namely pallidotomy (Lozano et al., 1997; Vitek et al., 1998; Ford,
2004). Other surgical options include peripheral denervation and
intrathecal baclofen pump implantation, depending on the type
of dystonia being treated. Due to prior success in treating dystonia
with pallidotomy, the GPi became the natural DBS target for dys-
tonia treatment (Benabid et al., 1998; Lozano and Abosch, 2004;
Isaias et al., 2009). Surgical criteria for undergoing DBS typically
include a ﬁrm diagnosis of dystonia, conservative management
failure, and signiﬁcant disability secondary to the condition.
In patients age seven or older, the FDA has approved palli-
dal DBS for primary dystonia as well as cervical dystonia (also
knownas spasmodic torticollis).However, the FDAapproval of DBS
for dystonia is under a special designation called humanitarian
device exemption (HDE), meaning that the FDA has given special
approval because it recognizes that for rare conditions it would be
difﬁcult for a company to scientiﬁcally demonstrate effectiveness
of their device in the large number of patients that is normally
required and as such the use of this device has probable beneﬁt
to people that outweighs the risk of injury or illness from its use.
Both GPi and STN targets were included in the HDE labeling, but
most of the published literature focuses on GPi and will be the
focus of this review.
Primary dystonia
Among the various types of dystonia, primary generalized dysto-
nia is the best studied with regards to DBS treatment. Numerous
studies have focused speciﬁcally on GPi DBS for the treatment of
primary generalized dystonia, both with and without the TOR1A
mutation (Coubes et al., 2000; Bereznai et al., 2002; Katayama
et al., 2003; Krauss et al., 2003; Yianni et al., 2003; Krause et al.,
2004a; Vidailhet et al., 2005; Diamond et al., 2006; Kupsch et al.,
2006; Starr et al., 2006; Alterman et al., 2007; Tisch et al., 2007).
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These have all shown at least some improvement on the Burke–
Fahn–Marsden Dystonia Rating Scale (BFMDRS), the commonly
used standardized scale for primary generalized dystonia, with
most showing improvements of 60–70% on the movement score
(Ostrem and Starr, 2008). In a prospective, multicenter, random-
ized,controlled trial,Vidailhet et al. (2005) studied 22patientswith
primary generalized dystonia treated with GPi DBS. Patients were
followed 3, 6, and 12months postoperatively and BFMDRS scores
were compared to preoperative scores. The 3-month evaluation
included videotaped double-blind evaluations with and without
neurostimulation. Patients had a signiﬁcantmean improvement of
29% in the BFDRS movement scores while stimulated compared
to no stimulation. Furthermore, 12month scores showed mean
improvements of 54% in the BFMDRS movement score and 44%
in the BFMDRS disability score compared to preoperative base-
line. Following this landmark study,Kupsch et al. (2006) studied 40
patients with primary generalized or segmental dystonia treated
with GPi DBS randomized to either neurostimulation or sham
stimulation for a 3-month period. At 3months, patients receiv-
ing neurostimulation had a signiﬁcant mean improvement of 39.9
and 38% inBFMDRSmovement and disability scores, respectively,
compared to their counterparts receiving sham stimulation, who
had respective improvements of 4.9 and 11%.
In addition to short term clinical improvement, more recent
studies have shown long-term sustainability of these beneﬁts.
Vidailhet et al. (2007) reported their 3 year follow up on the
22 patients previously studied. BFMDRS motor and disability
scores observed at 3 years after treatment remained improved com-
pared to preoperative baselines at 58 and 46%, respectively. Mild
long-term improvement in quality of life and attention were also
observed. Isaias et al. (2009) reported on 30 consecutive patients
with at least 2 years and up to 8 years of follow up after pallidal
DBS. Clinical outcome as measured by changes in the BFMDRS in
23 patients were followed for 3 years, 13 for 4 years, 9 for 5 years,
5 for 6 years, 5 for 7 years, and 1 for 8 years after DBS. Overall
improvement at 1 year was maintained in all patients at succes-
sive yearly examinations, which led the authors to conclude that
pallidal DBS is a safe and effective treatment for primary general-
ized dystonia, with improvement sustained for up to 8 years in one
patient (Isaias et al., 2009). Health related quality of life (HRQoL)
has also been shown to signiﬁcantly improve after pallidal DBS.
As part of a randomized sham-stimulation controlled trial on pal-
lidal DBS in primary segmental or generalized dystonia, Muller et
al. assessed the HRQoL using the SF-36. After the 3-month sham-
controlled phase, signiﬁcantHRQoL improvements occurred only
in the active-stimulation group. The open-label extension phase
resulted in a signiﬁcant improvement in all SF-36 domains fol-
lowing 6months of neurostimulation. These results demonstrate a
favorable impact of DBS on HRQoL in primary dystonia (Mueller
et al., 2007).
Complications of GPi DBS for the treatment of dystonia are
similar to complications seen forDBS treatment of other disorders,
and include hemorrhage, infection, lead fracture, dysarthria, and
visual loss. Despite a signiﬁcant number of studies, there is limited
ability to predict which patients will receive the most beneﬁt from
pallidal DBS preoperatively (Ostrem and Starr, 2008). Patients
with andwithout theTOR1A mutation have been reported to have
similar results (Coubes et al., 2000; Vidailhet et al., 2005; Kupsch
et al., 2006). Furthermore, age of onset of the disease has also been
ruled out as a predictor of outcome. However, patients that have
had the disease for prolonged durations may fare more poorly due
to development of secondary ﬁxed contractures (Alterman et al.,
2007).
Patients with primary cervical dystonia (spasmodic torticollis)
who have failed conservative therapy with botulinum toxin have
been reported to gain signiﬁcant beneﬁt from GPi DBS (Krauss
et al., 1999; Bereznai et al., 2002; Goto et al., 2002; Hung et al.,
2007; Kiss et al., 2007). In the Canadian multicenter study of DBS
for cervical dystonia, Kiss et al. (2007) performed a prospective,
single-blind study of bilateral GPi DBS in 10 patients with severe,
chronic, medication-resistant cervical dystonia. Outcomes were
assessed by two blinded neurologists at 6 and 12months after
treatment using the Toronto Western Spasmodic Torticollis Rat-
ing Scale (TWSTRS), the most commonly used rating scale for
cervical dystonia. They found signiﬁcant mean improvements of
44, 64, and 65% in the TWSTRS severity, disability, and pain sub-
scores, respectively. Long-term sustained beneﬁt has been reported
byHung et al. (2007) in their series of 10 patients and up to 3 years
of postoperative follow up. There also reports of improvement in
patients withMeige syndrome (primary cranial–cervical dystonia)
after GPi DBS (Muta et al., 2001; Bereznai et al., 2002; Foote et al.,
2005; Houser andWaltz, 2005; Ostrem et al., 2007).
Secondary dystonia
Deep brain stimulation appears to work in some patients with
secondary dystonia. There have been reports of cases treated with
GPiDBS for dystonia secondary to pantothenate kinase-associated
neurodegeneration (Castelnau et al., 2005), X-linked dystonia
of parkinsonism (Evidente et al., 2007), post-traumatic dystonia
(Yianni et al., 2003; Starr et al., 2006), cerebral palsy associated
dystonia (Zorzi et al., 2005; Starr et al., 2006), postencephalitic
dystonia (Zorzi et al., 2005), and post-stroke dystonia. In gen-
eral however, these conditions do not respond as consistently or
markedly as primary dystonia (Ostrem and Starr, 2008). One rea-
son for the varied response of DBS for patients with secondary
dystonia is that secondary dystonia has several different causes
including stroke, trauma, infections,metabolic abnormalities, and
cerebral palsy. As a result, the brain areas involved in causing
the dystonia are also likely to differ. Therefore, DBS in the GPi
may not affect the structure(s) that cause the dystonic movements
in patients with secondary dystonia. The one likely exception is
tardive dystonia (dystonia that is caused by speciﬁc drugs called
neuroleptics or the gastrointestinal medications metoclopramide
and prochlorperazine) where there is growing evidence of signif-
icant improvement in dystonic symptoms from DBS that appears
to be comparable to the results in primary generalized dystonia
(Yianni et al., 2003; Eltahawy et al., 2004; Krause et al., 2004a; Starr
et al., 2006; Damier et al., 2007). Damier et al. (2007) performed
a prospective, multicenter, double-blind study of 10 patients with
medically refractory tardive dyskinesia treated with bilateral GPi
DBS. Successful outcome was deﬁned as more than 40% decrease
in the Extrapyramidal Symptoms Rating Scale at 6months. At the
6-month mark, all 10 patients had a successful outcome based on
this measure and there was a mean improvement of 50% when
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stimulation was applied compared to the absence of stimulation.
The authors concluded that although larger studies are needed,
GPi DBS does seem to offer a much needed treatment for this
patient population.
MECHANISM OF ACTION OF DBS
While the clinical beneﬁts of DBS, particularly in the treatment of
movement disorders, are well-established, the biological mecha-
nisms of action underlying these effects still remain unclear. Three
primary hypotheses have been proposed (Hammond et al., 2008;
Tye et al., 2009). The ﬁrst explanation is that high frequency DBS
silences stimulated neurons. Because DBS and ablative surgery
have similar therapeutic effects, the stimulation-evoked silencing
of pathologically hyperactive neurons was initially postulated as
the primarymechanism (Benabid et al., 1987, 2000; Bergman et al.,
1990). This notion was further supported by early work mea-
suring STN electrophysiology during DBS (Beurrier et al., 2001;
Magarinos-Ascone et al., 2002).However,more recent studies have
reported the activation of STN output nuclei with high frequency
stimulation, suggesting this hypothesis may be overly simplistic
(Garcia et al., 2003).
The second general hypothesis is that high frequency stim-
ulation modulates neuronal network activity and neurotrans-
mission. Electrophysiology studies have clearly demonstrated
increased activity in target neurons, consistent with axonal activa-
tion during DBS (Benazzouz and Hallett, 2000; Hashimoto et al.,
2003;Miocinovic et al., 2006). Pre-clinical studies have also shown
neurotransmitter release in various efferent targets during DBS
(Windels et al., 2000, 2003). To better understand the region-
speciﬁc effects of DBS on neurotransmission, a MRI-compatible
device called the wireless instantaneous neurotransmitter con-
centration system (WINCS) has been developed (Shon et al.,
2010a; Van Gompel et al., 2010; Figure 4). This device is capable
of monitoring the release of a variety of neurochemicals dur-
ing DBS using the electroanalytical techniques of fast-scan cyclic
voltammetry at a carbon ﬁber microelectrode (Bledsoe et al.,
2009) and ﬁxed potential amperometry (Agnesi et al., 2009) at
enzyme-linked biosensors. WINCS has been used to demonstrate
dopamine release in the caudate during STN DBS in the intact
rat and pig (Shon et al., 2010b), as well as the parkinsonian rat
6-OHDAmodel (Lee et al., 2006; Shon et al., 2009). Most recently,
WINCS has also shown that there is adenosine release in the cau-
date during DBS in the rat (Shon et al., 2009). Taken together,
these studies monitoring neurotransmitter release strongly sug-
gest that DBS may modulate speciﬁc neurons that release spe-
ciﬁc neurotransmitters, thereby affecting these systems in the
brain.
The third hypothesis is that high frequency stimulation induces
long-term synaptic changes (plasticity). This has been inferred
from the often seen delayed time course of therapeutic effects
of stimulation. For example, the therapeutic effects of GPi DBS
for dystonia may take months to occur despite consistent high
FIGURE 4 |Wireless instantaneous neurotransmitter concentration
system (WINCS). (A) Photograph of theWINCS circuit board demonstrating
the size, microprocessor, and Bluetooth components. (B) Photograph of
WINCS sterilizable casing and the reference and working electrode leads. (C)
Pseudocolor plot of stimulated dopamine in a pig with the Medtronic 3389
electrode in the STN and theWINCS carbon ﬁber in the caudate nucleus. The
stimulation parameters are: 3mA, 120Hz, 2 s stim, 0.5ms pulse width. The
y -axis is the voltage cycled from −0.4V at the top, to +1.5V in the middle,
and −0.4V in the bottom; the x -axis is time. These scans occur 10 times
per second and take 1/100 of a second. The scan parameters are cyclic, −0.4
to +1.5 to −0.4V. The current is also recorded in nanoamps and shown by the
color bar on the right. Inset at the upper right corner is the unfolded
subtracted voltammogram. The oxidation peak is at +0.6V which is typical for
dopamine; the downward deﬂection is the reduction peak.
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frequency stimulation from the early postoperative period, in
contrast to the relative early improvement seen in PD patients
with DBS (Ostrem et al., 2007).
Clariﬁcation of these potential biologicalmechanisms of action
is imperative to helpmaximize the therapeutic efﬁcacy of DBS and
minimize unwanted side effects (Tye et al., 2009). Current and
future studies are aimed at further elucidating these mechanisms
to expandonand improve this growing therapeuticmodality in the
treatment of not only movement disorders, but also other neuro-
logic diseases and conditions such as psychiatric disorders. Among
the various techniques aimed at better understanding the underly-
ing mechanism of DBS, the ﬁeld of optogenetics holds particular
promise. Optogenetics is a novel technique that combines genetic
targeting of speciﬁc neurons or proteins with optical technology to
control speciﬁc events in targeted cells of living organisms (Deis-
seroth et al., 2006). Neuro-optogenetics utilizes light-gated ion
channels that can activate or inhibit neuronal signaling (Banghart
et al., 2004; Gunaydin et al., 2010; Toettcher et al., 2011). Gradi-
naru et al. (2009) utilized this technique to deconstruct the neural
circuitry underlying PD in a rat model. They argue that this tech-
nique overcomes some of the barriers to understanding the DBS
mechanism because it allows very selective sensitization of indi-
vidual neural circuit components and therefore hypothesis testing
for individual cell types without associated complications typi-
cally seen fromDBS (such as soma–axon decoupling and electrical
stimulus artifacts). In their experiment, they systematically stim-
ulated or inhibited various distinct elements of the neural circuit
associated with PD and found that direct selective stimulation of
the afferent axons to the STN could mimic the therapeutic effects
of DBS of the STN in their ratmodel. Interestingly, they also found
that optically induced high frequency stimulation of the layer V
motor cortex projections to the STN resulted in similar effects.
Experiments and techniques such as these likely hold the keys
to unlocking our understanding of the underlying mechanisms
of DBS.
SUMMARY
Deep brain stimulation is a highly effective, safe, and reversible
surgical treatment for advanced PD, tremor, and dystonia. Each
of these disorders has obvious differences, but also has striking
similarities with regards to symptoms, DBS target, stimulation
parameters, and clinical effects. While this ﬁeld has grown expo-
nentially in the last 20 years, a better understanding of the intricate
neurocircuitry associated with these disorders, as well as how DBS
can produce such amazing therapeutic beneﬁts, will unlock the
door to even more possibilities.
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